{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:15Z","timestamp":1791581895788,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Growing evidence supports gene fusions as good candidates for molecularly targeted therapy in CRC. Here we describe a case of a 63-year-old man who had a radical right hemicolectomy procedure 24 months ago. Pathological diagnosis indicated colorectal adenocarcinoma with stage pT4N2bMx. During re-examination in December 2016, positron emission tomography\/computed tomography scans indicated relapse with multiple lymph nodes metastasis. Then the patient received a nine-cycle combination treatment of XELOX and bevacizumab and showed progressive disease (PD). Subsequently, the patient was treated with bevacizumab plus FOLFIRI for 2 months before discontinuation because of adverse events. Paraffin sections of postoperative colorectal tissue were subjected to next-generation sequencing, and epidermal growth factor receptor (EGFR) amplification and rare EGFR\u2013SEPT14 fusion were identified. The patient then received erlotinib, an EGFR tyrosine kinase inhibitor (TKI), and achieved a partial response. However, the patient subsequently showed PD, and a new variant, EGFRvIII, appeared in metastasis, which may be involved in erlotinib resistance. We suggest that there is value in treating patients harboring EGFR fusions with EGFR TKI therapy, and EGFR\u2013SEPT14 fusion may be used as a therapeutic target for CRC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>To the authors' knowledge, this is the first report of EGFR\u2013SEPT14 fusion in colorectal cancer. The patient achieved a partial response after treatment with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. This report expands the list of gene fusions in colorectal cancer and highlights new targets for the therapeutic intervention. EGFRvIII may be involved in erlotinib resistance, which is rare in colorectal cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0405","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T19:25:11Z","timestamp":1571772311000},"page":"203-207","source":"Crossref","is-referenced-by-count":23,"title":["A Rare <i>EGFR<\/i>\u2013<i>SEPT14<\/i> Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib"],"prefix":"10.1093","volume":"25","author":[{"given":"Yong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Image, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojie","family":"Zheng","sequence":"additional","affiliation":[{"name":"OrigiMed, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"OrigiMed, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"2021122510133791500_R1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2021122510133791500_R2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-4827(71)90223-0","article-title":"Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis","volume":"69","author":"Hartwell","year":"1971","journal-title":"Exp Cell Res"},{"key":"2021122510133791500_R3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1091\/mbc.e09-10-0869","article-title":"Septin 14 is involved in cortical neuronal migration via interaction with septin 4","volume":"21","author":"Shinoda","year":"2010","journal-title":"Mol Biol Cell"},{"key":"2021122510133791500_R4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0004.2010.01392.x","article-title":"Conquering the complex world of human septins: Implications for health and disease","volume":"77","author":"Peterson","year":"2010","journal-title":"Clin Genet"},{"key":"2021122510133791500_R5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","article-title":"ERBB receptors: Directing key signaling networks throughout life","volume":"44","author":"Holbro","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122510133791500_R6","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"key":"2021122510133791500_R7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR fusions as novel therapeutic targets in lung cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Cancer Discov"},{"key":"2021122510133791500_R8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2021122510133791500_R9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"45","author":"Frattini","year":"2013","journal-title":"Nat Genet"},{"key":"2021122510133791500_R10","doi-asserted-by":"crossref","first-page":"e13538","DOI":"10.1200\/JCO.2018.36.15_suppl.e13538","article-title":"Prevalence of EGFR gene fusions in a large cohort of Chinese patients with non-small cell lung cancer (NSCLC)","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122510133791500_R11","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-1905","article-title":"Gefitinib induces apoptosis in the EGFRl858R non-small-cell lung cancer cell line H3255","volume":"64","author":"Tracy","year":"2004","journal-title":"Cancer Res"},{"key":"2021122510133791500_R12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112420","article-title":"Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms","volume":"18","author":"Yamaoka","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"suppl 6","key":"2021122510133791500_R13","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdm222","article-title":"Erlotinib in cancer treatment","volume":"18","author":"Bareschino","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122510133791500_R14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/annonc\/mdh188","article-title":"Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors","volume":"15","author":"Giaccone","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122510133791500_R15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00384-011-1149-0","article-title":"Cetuximab and panitumumab in KRAS wild-type colorectal cancer: A meta-analysis","volume":"26","author":"Petrelli","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"2021122510133791500_R16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/hed.21858","article-title":"Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: A meta-analysis","volume":"34","author":"Petrelli","year":"2012","journal-title":"Head Neck"},{"key":"2021122510133791500_R17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/107327480701400313","article-title":"EGFR targeting of solid tumors","volume":"14","author":"Rocha-Lima","year":"2007","journal-title":"Cancer Control"},{"key":"2021122510133791500_R18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"The Oncologist"},{"key":"2021122510133791500_R19","first-page":"3140","article-title":"Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas","volume":"55","author":"Wikstrand","year":"1995","journal-title":"Cancer Res"},{"key":"2021122510133791500_R20","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1038\/sj.onc.1207602","article-title":"Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase\/AKT pathway and promotes radioresistance in cells of astrocytic origin","volume":"23","author":"Li","year":"2004","journal-title":"Oncogene"},{"key":"2021122510133791500_R21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"Bent","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122510133791500_R22","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122510133791500_R23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1758-3284-3-11","article-title":"The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"3","author":"Chau","year":"2011","journal-title":"Head Neck Oncol"},{"key":"2021122510133791500_R24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7150\/jca.16108","article-title":"Low incidence along with low mRNA levels of EGFRvIII in prostate and colorectal cancers compared to glioblastoma","volume":"8","author":"Peciak","year":"2017","journal-title":"J Cancer"},{"key":"2021122510133791500_R25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.18632\/oncotarget.26722","article-title":"Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer","volume":"10","author":"Khelwatty","year":"2019","journal-title":"Oncotarget"},{"key":"2021122510133791500_R26","first-page":"4889","article-title":"Lack of the type III epidermal growth factor receptor mutation in colorectal cancer","volume":"26","author":"Spindler","year":"2006","journal-title":"Anticancer Res"},{"key":"2021122510133791500_R27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/neuonc\/not093","article-title":"Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta","volume":"15","author":"Schulte","year":"2013","journal-title":"Neuro Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/203\/41918756\/oncolo_25_3_203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/203\/41918756\/oncolo_25_3_203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:15:49Z","timestamp":1640427349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/3\/203\/6443393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,22]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0405","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2019,10,22]]}}}